Features of the Drug Therapy of Children with Systemic Juvenile Idiopathic Arthritis: Analysis Results of the All-Russian Register of the Union of Pediatricians of Russia

• Main Authors: E. I. Alexeeva (Author), O. L. Lomakina (Author), S. I. Valieva (Author), T. M. Bzarova (Author), I. P. Nikishina (Author), Ye. S. Zholobova (Author), G. G. Torosyan (Author), S. R. Rodionovskaya (Author), M. I. Kaleda (Author), L. A. Galstyan (Author), I. B. Alakaeva (Author), Ye. A. Korotkova (Author), A. V. Artyomov (Author), D. Yu. Vurdov (Author)
• Format: Book
• Published: "Paediatrician" Publishers LLC, 2016-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Objective: Our aim was to study features of the drug therapy of children with systemic juvenile idiopathic arthritis (sJIA).Methods: We conducted a retrospective data analysis included in the Register of sJIA cases, for the period from 2002 to 2015.Results: The indicators of 384 children with sJIA are studied. Prior to the diagnosis verification, all patients were prescribed to intake antipyretic agents, 98% - antibiotics. After the diagnosis, non-steroidal anti-inflammatory drugs (NSAIDs) were intaken by 282 (73.4%) patients: diclofenac sodium - by 163 (40.1%), nimesulide - by 88 (22.9%) patients. The average duration of NSAID intake from 2002 to 2015 decreased from 81.5 ± 115.3 to 3.3 ± 3.7 months (p < 0.001). Prior to the diagnosis verification, glucocorticoids were received intravenously or intramuscularly by 265 (69.0%) patients, orally - 176 (45.8%). Totally, glucocorticoids were received by 330 (85.9%) patients: methylprednisolone - 300 of 384 (78.1%), prednisolone - 174 (45.3%), there were totally 1855 prescriptions in 668 patients. The average duration of glucocorticoid intake from 2002 to 2015 decreased from 13.7 ± 26.7 to 5.0 ± 3,8 months (p < 0.001). As a disease-modifying drug, methotrexate was intaken by 237 (61.7%), Cyclosporin - by 193 (50.6%) patients. There were totally 809 prescriptions of genetically engineered biological preparations (GIBP) in 430 patients: in 2002-2005-8, in 2011-2015-602 in 397 patients (p = 0.001). Tocilizumab is intaken by 210 (52.9%) of 397 patients, kanakinumab - 37 (9.3%) patients. The disease duration from the manifestation to the prescription of immunosuppressive drugs from 2002 to 2015 decreased from 27.3 ± 23.9 to 1.0 ± 0 months (p < 0.001), GIBP prescriptions - from 70.7 ± 26.3 to 0.5 ± 0.7 months, respectively (p < 0.001).Conclusion: In 13 years there have been positive changes in the antirheumatic therapy in children with sJIA - the duration of NSAIDs and glucocorticoids intake reduced, the period between diagnosis verification and immunosuppressants and GIBP prescription decreased. However, it is still widely used antibiotics, non-selective NSAIDs and glucocorticoids.

Item Description

1682-5527
1682-5535
10.15690/vsp.v15i1.1500